In late 2025, SELLAS Life Sciences Group reported encouraging Phase 2 data for SLS009 in combination with azacitidine and venetoclax in relapsed or refractory acute myeloid leukemia and confirmed that ...
Patients testing positive for NPM1 MRD pre-alloHCT have significantly increased rates of relapse, reduced overall survival ...
Acute Myeloid Leukemia is the most common acute leukemia in adults affecting 2-6 adults per 100,000k globally. -With relapse ...
Gina Young is an accomplished finance writer who has written for publications including SuperMoney, Examiner, Lexington Law, Talk Markets, and CreditRepair.com. Throughout her career in finance, Gina ...
Blackstone Life Sciences (“BXLS”) today announced a research and development funding agreement to advance the clinical development of bleximenib (JNJ-75276617), an investigational oral menin inhibitor ...
Multiple sclerosis (MS) is a chronic, disabling, inflammatory disease that damages your nerves. People with MS typically live roughly seven years less than the general population, with an average life ...
Kerynn Morss is still looking for a donor match for her son Broeden Sabin, who was diagnosed with acute myeloid leukemia in December 2025 Wendy Grossman Kantor is an award-winning journalist who has ...
Clinical Impact and Clinicopathologic Correlations of Oncotype DX in Hormone Receptor–Positive/HER2–Negative Early Breast Cancer: Real-World Evidence From a Large ...
Frontline patient outcomes are making the case for mipletamig to enhance standard-of-care therapy alongside venetoclax + azacitidine SEATTLE, WA / ACCESS Newswire / March 10, 2026 / Aptevo ...
ST. LOUIS, MO, UNITED STATES, February 23, 2026 /EINPresswire.com/ — Pairidex, an emerging leader in leukemia detection, today announced a lead investment from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results